article thumbnail

Open Targets Platform 25.06 has been released!

The Open Targets Blog

The Platform does not have direct genetic evidence to link IFNAR1 to SLE, but there is an approved therapy, Anifrolumab, targeting IFNAR1 for SLE. New data downloads page and Croissant We have revamped our data downloads page , making it easier for you to find the dataset you need.

article thumbnail

Key Trends Drug Developers Need to Know to Succeed

PPD

These internal issues are compounded by external pressures like inflation, the development of innovative therapies that require complex protocols and the need to comply with shifting regulatory requirements. Download the full report The post Key Trends Drug Developers Need to Know to Succeed appeared first on PPD.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Abandoned oncology drugs -Identifying new indications using active machine learning and a biobank of patient derived dissociated tumor cells (DTCs)

Predictive Oncology

Our study revealed several drugs with potential to outperform standard therapies in certain cancers—and they could be ready for the clinic much quicker than any single new drug. Fill out the form below to download the full whitepaper and explore the complete data and analysis. Complete the form below to download the white paper.

article thumbnail

The Real Cost of Complexity: What Every Drug Developer Needs to Know

PPD

Internal costs: The complexity of protocol designs a necessity for innovative therapies often requires more diverse patient populations, more extensive data collection and sophisticated trial methodologies, all of which demand higher financial outlays. Nearly 39% of sponsors cite these costs as primarily driven by complex protocols.

article thumbnail

How FSP Solutions Support Risk-Based Methodologies and Tech Innovation in Clinical Operations

PPD

By harnessing the full range of innovative technologies and taking advantage of an FSP partners extensive skills and experience, sponsors are able to bring their therapies to market more quickly and within budget even in the face of complicated global regulations and widely fluctuating workloads.

article thumbnail

Inside The Altascientist: Understanding Drug Interaction Factors for Safer, More Effective Therapies

Alta Sciences

Listen to the audiobook or download the PDF below, to learn more about: key factors to consider in drug development (age, biological sex, genetics, DDIs); examples of common DDI involving the cytochrome P450 enzyme system; and drug interactions and guidance for marketed drugs.

article thumbnail

Eight Key Considerations for Evaluating FSP Partners Offering Remote-Based Regional Hubs

PPD

By breaking free from geographical constraints, these companies enhance flexibility, efficiency and speed to market, ensuring a continuous workflow and faster delivery of new therapies. Download our white paper The post Eight Key Considerations for Evaluating FSP Partners Offering Remote-Based Regional Hubs appeared first on PPD.